Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
Active, not recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT06519097
This is a randomized, double-blind, placebo-controlled trial, investigating whether treatment with δ-tocotrienol (a.k.a. Delta-tocotrienol, abbreviated as DT3) will prevent the progression of Intraductal Papillary Mucinous Neoplasm (IPMN) of the pancreas.
Intervention
Placebo, Vitamin E Delta Tocotrienol
Condition
Neoplasm of Pancreas, IPMN, Pancreatic
Investigators
Mokenge P Malafa, MD, FACS